Clesrovimab in Infants at Increased Risk For Severe Disease During 2 RSV Seasons Authors: Heather J. Zar, Louis J. Bont, Paolo Manzoni, Flor M. Muñoz, Octavio Ramilo, Po-Yen Chen, José M Novoa, Gustavo A. Ordoñez, Maria Tsolia, Bruce Tapiéro, Mirta I. Acuña-Ávila, Javier M. Castellanos, Michael Meyer, Ichiro Morioka, Santtu Heinonen, Ziqiang Chen, Tiantian Zeng, Radha A. Railkar, Carmen Sofia Arriola, Xiaowei Zang, Christine Hildebrand, Alvino Maestri, Luis A. Castagnini, Anushua Sinha Published: 2026 ABSTRACT Key PointsQuestionHow does the safety profile of single-dose clesrovimab compare with that of monthly palivizumab in infants at increased risk for severe RSV disease in their first RSV season, and what is the safety profile of a second season 210-mg dose of clesrovimab given to children who remain at risk for severe disease?FindingsIn this randomized clinical trial of 997 dosed infants at increased risk of severe RSV disease due to prematurity, chronic lung disease of prematurity, or hemodynamically significant congenital heart disease, the proportions of participants experiencing adverse events were comparable between treatment groups in season 1. A 210-mg dose of clesrovimab given to 276 children who remained at risk of severe disease in their second RSV season was generally well tolerated.MeaningClesrovimab was well tolerated through 2 RSV seasons; these findings support the use of clesrovimab in children who remain at risk for severe RSV disease in their second RSV season. Introduction Respiratory syncytial virus (RSV) is one of the most common causes of acute lower respiratory infection (LRI) and hospitalization among infants worldwide, leading to a substantial number of infant deaths annually, most occurring in low- and middle-income countries.1 All infants are at risk for RSV disease, particularly in the first 6 months of life.2,3 Preterm infants and those with comorbidities such as chronic lung disease (CLD) of prematurity, congenital heart disease (CHD), or other certain conditions are at an increased risk for severe RSV disease.4,5 Moreover, children with these comorbidities continue to be at increased risk in their second year of life.6,7 For decades, the standard of care for RSV prevention in high-risk infants was the short-acting monoclonal antibody (mAb) palivizumab8 (Synagis; MedImmune). More recently, nirsevimab9,10,11 (Beyfortus; AstraZeneca and Sanofi Pasteur), a long-acting mAb targeting antigenic site Ø of RSV fusion (F) protein, has been approved for RSV prevention in infants dosed by weight. A bivalent RSV prefusion F maternal immunization, RSVPreF12 (ABRYSVO; Pfizer) can be given during pregnancy to protect infants from birth through 6 months. Clesrovimab (ENFLONSIA; Merck & Co, Inc), another long-acting RSV mAb, was approved for the prevention of RSV lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season as a single fixed dose, regardless of weight. Clesrovimab achieves high nasal tissue distribution at the site of RSV infection13 and targets a highly conserved site within antigenic site IV of RSV F protein.14,15,16,17,18 The phase 2b/3 CLEVER trial19 demonstrated that clesrovimab was well tolerated and efficacious in reducing RSV-associated disease and hospitalization in healthy infants.20 We previously reported prespecified interim results from the phase 3, randomized, palivizumab-controlled, SMART trial21 evaluating clesrovimab in infants at increased risk for severe RSV disease.22,23 Here, we report the SMART end-of-study results through 2 RSV seasons. Methods Study Design and Participants SMART (Protocol MK-1654-007) was a phase 3, randomized, partially masked, active comparator-controlled trial conducted between November 30, 2021, and November 20, 2025, at 110 sites in 27 countries and territories (eTables 1 and 2 in Supplement 1). Participants were infants recommended to receive palivizumab based on local guidelines due to premature birth (≤35 weeks gestational age), CLD of prematurity, or hemodynamically significant CHD, entering their first RSV season. Key exclusion criteria included severe immunodeficiency or previous receipt of any vaccine (including maternal vaccination) or mAb for the prevention of RSV. Inclusion and exclusion criteria are listed in the eAppendix in Supplement 1. The trial was conducted in accordance with principles of Good Clinical Practice and was approved by the appropriate institutional review boards and regulatory agencies (listed in eTable 3 in Supplement 1). This trial was reported in accordance with CONSORT reporting guidelines. Each participant’s legal representative provided documented informed consent for the study. This study was sponsored by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc (MSD). Race and ethnicity were collected based on caregiver self-report using options determined by the sponsor and are reported to evaluate the representativeness and generalizability of the findings. The trial protocol is available in Supplement 2. Randomization, Blinding, and Interventions In RSV season 1, participants were randomized, stratified by region (northern or southern hemisphere) and condition (CLD, CHD, extreme preterm [<29 weeks’ gestational age] with neither CLD nor CHD, or early to moderate preterm [≥29-35 weeks’ gestational age] with neither CLD nor CHD) 1:1 to clesrovimab (105 mg) or palivizumab (15 mg/kg body weight) (eFigure 1 in Supplement 1). At day 28, the clesrovimab group received placebo (0.9% sodium chloride), and the palivizumab group received a second dose of palivizumab. An independent statistician generated the randomized allocation schedule (block size = 4), which was implemented using a centralized electronic interactive response technology system. The syringes containing clesrovimab, placebo, and palivizumab were prepared by an unblinded trial pharmacist and were indistinguishable. Double masking was maintained through day 60. To spare infants in the clesrovimab group further placebo injections, the treatment group was unmasked at day 60 and a third palivizumab dose was administered to the palivizumab group. Optional fourth and fifth palivizumab doses were given to the palivizumab group participants on days 90 and 120 depending on enrollment date relative to the RSV season, consistent with local standard of care. Open-label clesrovimab (210 mg) was administered up to 4 weeks before RSV season 2 in participants who were eligible to participate in 2 RSV seasons based on their continued risk of severe RSV disease due to CLD, CHD, or early or moderate prematurity and additional risk factors (eAppendix in Supplement 1).22 An unscheduled additional dose of either treatment could be administered during either season if a participant underwent extracorporeal membrane oxygenation (ECMO) or surgical intervention for CHD requiring cardiopulmonary bypass. Main Outcome Measures Safety Outcomes The primary objective was to evaluate the safety and tolerability of clesrovimab compared with palivizumab in RSV season 1. Primary end points were the proportion of participants experiencing solicited (injection site and systemic) adverse events (AEs) and solicited daily body temperature to assess fever (≥102.2 °F rectal or ≥101.7 °F axillary) from day 1 to 5 after any dose; adverse events of special interest (AESIs) of anaphylaxis and/or hypersensitivity and rash through 42 days after dose 1; nonserious AEs from day 1 to 42 after dose 1 and 14 days after each subsequent dose; and serious adverse events (SAEs) throughout season 1. AEs occurring after any dose refers to the time frame following any injection of clesrovimab, placebo, or any dose of palivizumab during season 1. A secondary objective was to describe the safety of clesrovimab (210 mg) in season 2 (eAppendix in Supplement 1). Solicited AEs were recorded in an electronic diary by the participant’s legal representative and subsequently assessed and reported by the investigator. AEs were coded in accordance with the Medical Dictionary for Regulatory Activities, version 28.1, and graded from 1 to 5. Safety follow-up occurred through 365 days after dose 1 (clesrovimab or palivizumab) in season 1 for infants participating in season 1 only, through the day prior to the season 2 dose for individuals participating in both seasons, and through 180 days after clesrovimab (210 mg) in season 2. RSV-Associated Disease Outcomes Additional secondary objectives were to evaluate the incidence of RSV-associated medically attended (inpatient or outpatient) lower respiratory infection (MALRI) requiring at least 1 indicator of LRI or severity and incidence of RSV-associated hospitalization from days 1 to 150 (eTable 4 in Supplement 1). Exploratory objectives evaluated incidence of a range of RSV-associated disease end points. To identify cases of RSV-associated disease, weekly active surveillance was conducted 180 days after the first dose of clesrovimab (105 mg) or palivizumab in season 1 and after a 210-mg dose of clesrovimab in season 2. Active surveillance was conducted via an electronic questionnaire or telephone call to the participant’s representative to determine whether the participant had signs or symptoms or had been to a medical facility for care of a respiratory infection. Additionally, participant representatives were instructed to contact the site to report any respiratory infection symptoms, symptoms of concern, or any outpatient or inpatient visits. If any were reported, participants were assessed for respiratory infection. If specified respiratory symptoms were confirmed upon assessment, a nasopharyngeal swab was collected for reverse transcription–polymerase chain reaction by a central laboratory for RSV-A/RSV-B and other respiratory viruses. RSV F sequencing was performed on samples from infants with RSV infections. Pharmacokinetic, Pharmacodynamic, and Immunogenicity Outcomes Another secondary objective was to describe clesrovimab pharmacokinetics (PK). Sparse sample collection was used to minimize pediatric blood draws. PK, serum neutralizing antibody (SNA) titers, and antidrug antibody (ADA) levels were measured as previously described24 in samples collected from clesrovimab recipients at various time points in both seasons (eAppendix in Supplement 1). Sample Size Calculation With a sample size of 500 participants in the clesrovimab group (1000 total participants), the study provided 97.5% confidence that the underlying percentage of participants with an SAE is less than 0.74% if no SAEs were observed in the clesrovimab group. This assumed that 100% of the randomized participants would be evaluable for safety. Statistical Analysis This was an estimation trial without hypothesis testing. Missing data were not imputed. Safety analyses were performed on the all participants as treated (APAT) population: all randomized participants according to the study treatment that they received. Participants who incorrectly received a mixed regimen were excluded from the APAT population. Estimates of 95% CIs for between-treatment differences in the percentage of participants with events were calculated using the Miettinen and Nurminen method.25 Analyses of RSV-associated disease incidence were based on the full analysis set population: all randomized participants who received at least 1 dose of study treatment and were not excluded due to certain protocol deviations. Incidence rates were calculated through 5 months (days 1-150 after injection) and 6 months (days 1-180), and exact 95% CIs were calculated using the χ2 distribution for Poisson variable method.26 PK analyses were based on the per-protocol population: all randomized participants who received a dose of clesrovimab and did not have protocol deviations that may have substantially affected the results. Participants who received ECMO or cardiopulmonary bypass within the protocol-defined PK evaluation window were excluded from analysis. Results Participants In RSV season 1, 1003 participants were enrolled and randomized, of whom 997 were dosed: 498 received 105 mg of clesrovimab and 499 received palivizumab (Figure). Overall, 28.1% of participants had CLD, 10.6% had CHD, and 61.3% were born preterm (≤35 weeks’ gestational age) without CLD/CHD. Baseline characteristics were generally comparable between treatment groups in season 1 (Table 1). The median age at randomization was 2.6 months (range, 0.0-12.0 months), and the median weight was 3.3 kg (range 1.0-9.6 kg). Among the 997 dosed patients, 500 (50.2%) were male and 497 (49.8%) female; 166 (16.6%) were African American or Black, 176 (17.7%) were Asian, 505 (50.7%) were White, 128 (12.8%) were of multiple races, and 22 (2.2%) were of other race (including American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, and missing). In RSV season 2, 276 participants received 210 mg of clesrovimab (eTable 5 in Supplement 1). The median age at the second season dose was 14.4 months (range, 9.0-23.3 months), and the median weight was 8.4 kg (range, 4.2-13.9 kg). CONSORT Flow Diagram Safety analyses were based on the all participants as treated (APAT) population, which included all randomized participants who received at least 1 dose of study intervention according to the study intervention they actually received. aDose 2 for the clesrovimab group consisted of placebo. bOne participant in the clesrovimab group was excluded from the APAT population because they received clesrovimab at dose 1 and palivizumab (instead of placebo) at dose 2; this participant was excluded from the safety analyses, and their safety data were listed separately. cOne additional death occurred 133 days after season 2 study completion and is not captured here. Table 1. Baseline Characteristics for Participants Enrolled in RSV Season 1aCharacteristicClesrovimab (n = 498)Palivizumab (n = 499)Total (n = 997)Sex Male252 (50.6)248 (49.7)500 (50.2) Female246 (49.4)251 (50.3)497 (49.8)Age, mo <6455 (91.4)429 (86.0)884 (88.7) ≥6 to <935 (7.0)57 (11.4)92 (9.2) ≥98 (1.6)13 (2.6)21 (2.1) Mean (SD)3.0 (2.0)3.1 (2.4)3.1 (2.2) Median (range)2.7 (0.2-11.4)2.4 (0.0-12.0)2.6 (0.0-12.0)Gestational age, wk <29123 (24.7)132 (26.5)255 (25.6) ≥29 to <35323 (64.9)314 (62.9)637 (63.9) ≥3552 (10.4)53 (10.6)105 (10.5) Mean (SD)31.5 (3.3)31.5 (3.6)31.5 (3.5) Median (range)31.9 (23.6-41.1)32.0 (23.0-41.0)32.0 (23.0-41.1)Body weight, kg Mean (SD)3.7 (1.4)3.7 (1.5)3.7 (1.5) Median (range)3.4 (1.0-9.6)3.2 (1.5-9.1)3.3 (1.0-9.6)Race and ethnicity African American or Black81 (16.3)85 (17.0)166 (16.6) Asian90 (18.1)86 (17.2)176 (17.7) White250 (50.2)255 (51.1)505 (50.7) Multiple66 (13.3)62 (12.4)128 (12.8) Otherb11 (2.2)11 (2.2)22 (2.2)Regionc Northern hemisphere351 (70.5)352 (70.5)703 (70.5) Southern hemisphere147 (29.5)147 (29.5)294 (29.5)Climate (Sub)tropical86 (17.3)84 (16.8)170 (17.1) Temperate412 (82.7)415 (83.2)827 (82.9)Underlying conditionc CLD138 (27.7)142 (28.5)280 (28.1) CHD54 (10.8)52 (10.4)106 (10.6) No CLD/CHD, <29 wk GA41 (8.2)38 (7.6)79 (7.9) No CLD/CHD, 29-35 wk GA265 (53.2)267 (53.5)532 (53.4)Abbreviations: CHD, congenital heart disease; CLD, chronic lung disease; GA, gestational age; n, total number of participants per study arm (all dosed participants population). a Data shown are for the all dosed participants population. All values are the number of participants who met the corresponding criterion (%), unless otherwise specified. b Includes participants identified by their caregiver as American Indian or Alaska Native or Native Hawaiian or Other Pacific Islander, or for whom race was missing. c Stratification factor. Baseline Characteristics for Participants Enrolled in RSV Season 1a Abbreviations: CHD, congenital heart disease; CLD, chronic lung disease; GA, gestational age; n, total number of participants per study arm (all dosed participants population). Data shown are for the all dosed participants population. All values are the number of participants who met the corresponding criterion (%), unless otherwise specified. Includes participants identified by their caregiver as American Indian or Alaska Native or Native Hawaiian or Other Pacific Islander, or for whom race was missing. Stratification factor. Safety Outcomes The proportions of participants with AEs, including solicited AEs, drug-related AEs, and SAEs were generally comparable between the treatment groups in RSV season 1 (374 of 497 [75.3%] with ≥1 AE in the clesrovimab, 105 mg group vs 397 of 499 [79.6%] in the palivizumab group) (Table 2). The proportions of participants with AEs in RSV season 2 were comparable between those who had received clesrovimab or palivizumab in season 1 (92 of 138 [66.7%] with ≥1 AE among participants who received clesrovimab in season 1 vs 94 of 138 [68.1%] among participants who received palivizumab in season 1) (Table 3). Solicited injection-site AEs were observed among 18 of 276 children (6.5%) receiving a 210-mg dose (administered as two 105-mg injections) in season 2, the most common being injection-site pain. The majority of solicited AEs were grade 1 to 2 (eTables 6 and 7 in Supplement 1). Anaphylaxis or hypersensitivity AESIs were not reported in either season. The proportion of participants with a rash AESI was low in both seasons (3 [0.6%] in the clesrovimab group and 1 [0.2%] in the palivizumab group in season 1; 3 [1.1%] after 210 mg of clesrovimab in season 2; all grade 1). No participant discontinued due to an AE, and none of the reported SAEs were considered by the investigator to be related to clesrovimab in either season. There were 14 deaths; 12 occurred during season 1, 1 occurred during season 2, and 1 occurred 133 days after study completion. None were considered to be related to study treatment by the investigator (eTable 8 in Supplement 1). All deaths were attributable to underlying conditions or comorbidities or another clearly identifiable cause. RSV testing was performed for 6 of the 14 deaths, and all 6 were RSV negative. Table 2. Safety Summary for Season 1 (All-Participants-as-Treated Population)OutcomeNo. (%)% Difference vs palivizumab, estimate (95% CI)aClesrovimab, 105 mg (n = 497)Palivizumab (n = 499)Overall AEsb ≥1 AE374 (75.3)397 (79.6)−4.3 (−9.5 to 0.9) Drug-related AEsc152 (30.6)178 (35.7)−5.1 (−10.9 to 0.8) SAEs122 (24.5)137 (27.5)−2.9 (−8.4 to 2.5) Drug-related SAEsc0 (0.0)2 (0.4)−0.4 (−1.5 to 0.4) Deathsd8 (1.6)4 (0.8)0.8 (−0.6 to 2.4)Solicited AEs and fevere Solicited injection-site AEs74 (14.9)86 (17.2)−2.3 (−6.9 to 2.2) Injection site erythema31 (6.2)32 (6.4)−0.2 (−3.3 to 2.9) Injection site pain39 (7.8)54 (10.8)−3.0 (−6.7 to 0.7) Injection site swelling31 (6.2)28 (5.6)0.6 (−2.4 to 3.6) Solicited systemic AEs195 (39.2)208 (41.7)−2.4 (−8.5 to 3.6) Decreased appetite67 (13.5)66 (13.2)0.3 (−4.0 to 4.5) Irritability143 (28.8)168 (33.7)−4.9 (−10.6 to 0.9) Somnolence94 (18.9)110 (22.0)−3.1 (−8.2 to 1.9) With fever4 (0.8)6 (1.2)−0.4 (−1.9 to 1.0)AESIf Anaphylaxis or hypersensitivity AESI0 (0.0)0 (0.0)0.0 (−0.8 to 0.8) Rash AESI3 (0.6)1 (0.2)0.4 (−0.6 to 1.6)Abbreviations: AE, adverse event; AESI, adverse event of special interest; SAE, serious adverse event. a Differences and confidence intervals were estimated by the Miettinen & Nurminen method and were not adjusted for multiplicity. b Reported AEs include nonserious AEs from day 1 (ie, time of season 1 dose 1) through the day prior to dose 2 and 14 days after dose 2 and each subsequent dose, as well as SAEs that occurred throughout season 1. c Relatedness to treatment was determined by investigator. d None of the deaths were considered related to study intervention. e Solicited AEs and fever were documented at days 1 to 5 after any dose in season 1 and at days 1 to 5 after the 210-mg dose in season 2. f AESIs were documented at days 1 to 42 after dose 1 in season 1 and at days 1 to 42 after the 210-mg dose in season 2. Safety Summary for Season 1 (All-Participants-as-Treated Population) Abbreviations: AE, adverse event; AESI, adverse event of special interest; SAE, serious adverse event. Differences and confidence intervals were estimated by the Miettinen & Nurminen method and were not adjusted for multiplicity. Reported AEs include nonserious AEs from day 1 (ie, time of season 1 dose 1) through the day prior to dose 2 and 14 days after dose 2 and each subsequent dose, as well as SAEs that occurred throughout season 1. Relatedness to treatment was determined by investigator. None of the deaths were considered related to study intervention. Solicited AEs and fever were documented at days 1 to 5 after any dose in season 1 and at days 1 to 5 after the 210-mg dose in season 2. AESIs were documented at days 1 to 42 after dose 1 in season 1 and at days 1 to 42 after the 210-mg dose in season 2. Table 3. Safety Summary for Season 2 (All-Participants-as-Treated Population)OutcomeNo. (%)Previously received clesrovimab, 105 mg (n = 138)Previously received palivizumab (n = 138)Total (n = 276)Overall AEsa ≥1 AE92 (66.7)94 (68.1)186 (67.4) Drug-related AEsb28 (20.3)26 (18.8)54 (19.6) SAEs25 (18.1)26 (18.8)51 (18.5) Drug-related SAEsb0 (0.0)0 (0.0)0 (0.0) Deathsc1 (0.7)1 (0.7)2 (0.7)Solicited AEs and feverd Solicited injection-site AEs13 (9.4)5 (3.6)18 (6.5) Injection site erythema3 (2.2)2 (1.4)5 (1.8) Injection site pain7 (5.1)5 (3.6)12 (4.3) Injection site swelling4 (2.9)1 (0.7)5 (1.8) Solicited systemic AEs28 (20.3)30 (21.7)58 (21.0) Decreased appetite12 (8.7)7 (5.1)19 (6.9) Irritability12 (8.7)24 (17.4)36 (13.0) Somnolence15 (10.9)9 (6.5)24 (8.7) With fever0 (0.0)3 (2.2)3 (1.1)AESIe Anaphylaxis or hypersensitivity AESI0 (0.0)0 (0.0)0 (0.0) Rash AESI0 (0.0)3 (2.2)3 (1.1)Abbreviations: AE, adverse event; AESI, adverse event of special interest; SAE, serious adverse event. a Reported AEs include nonserious AEs that occurred from day 1 through 42 post-210-mg dose and SAEs that occurred from day 1 through 180 post-210-mg dose in season 2. b Relatedness to treatment was determined by investigator. c None of the deaths were considered related to study intervention. d Solicited AEs and fever were documented at days 1 to 5 after any dose in season 1 and at days 1 to 5 after the 210-mg dose in season 2. e AESIs were documented at days 1 to 42 after dose 1 in season 1 and at days 1 to 42 after the 210-mg dose in season 2. Safety Summary for Season 2 (All-Participants-as-Treated Population) Abbreviations: AE, adverse event; AESI, adverse event of special interest; SAE, serious adverse event. Reported AEs include nonserious AEs that occurred from day 1 through 42 post-210-mg dose and SAEs that occurred from day 1 through 180 post-210-mg dose in season 2. Relatedness to treatment was determined by investigator. None of the deaths were considered related to study intervention. Solicited AEs and fever were documented at days 1 to 5 after any dose in season 1 and at days 1 to 5 after the 210-mg dose in season 2. AESIs were documented at days 1 to 42 after dose 1 in season 1 and at days 1 to 42 after the 210-mg dose in season 2. Incidence of RSV-Associated Disease In season 1, the incidence rates of RSV-associated MALRI and of RSV-associated hospitalization through day 150 were comparable between clesrovimab (3.2% [95% CI, 1.8%-5.2%] and 1.0% [95% CI, 0.3%-2.4%], respectively) and palivizumab (3.4% [95% CI, 2.0%-5.6%] and 1.7% [95% CI, 0.7%-3.3%], respectively) (Table 4). Furthermore, the Kaplan-Meier curves for the clesrovimab and palivizumab groups overlapped (eFigure 2 in Supplement 1). RSV-associated disease incidence rates were similar between treatment groups across the range of end points (Table 4). Table 4. RSV-Associated Disease Incidence Rates for Season 1 (Full Analysis Set Population)aRSV-associated disease end pointEnd point designationClesrovimab (n = 498b)Palivizumab (n = 499b)No.cNo. of eventsTotal follow-up time, moIncidence rate (95% CI), %dNo.cNo. of eventsTotal follow-up time, modIncidence rate (95% CI), %d Season 1 incidence rates through 150 d (5 mo) after injection Severe MALRITertiary49542403.10.8 (0.2-2.1)48572367.31.5 (0.6-3.0)Hospitalization for LRITertiary49552398.51.0 (0.3-2.4)48582364.61.7 (0.7-3.3)HospitalizationSecondary49552398.51.0 (0.3-2.4)48582364.61.7 (0.7-3.3)MALRI requiring ≥2 indicators of LRI and severityTertiary49582397.81.7 (0.7-3.3)48592362.71.9 (0.9-3.6)MALRI requiring ≥1 indicators of LRI or severitySecondary495152375.03.2 (1.8-5.2)485162336.33.4 (2.0-5.6) Season 1 incidence rates through 180 d (6 mo) after injection HospitalizationTertiary49562869.31.3 (0.5-2.7)48582828.11.7 (0.7-3.3)MALRI requiring ≥2 indicators of LRI and severityTertiary49592865.51.9 (0.9-3.6)48592825.21.9 (0.9-3.6)MALRI requiring ≥1 indicators of LRI or severityTertiary495162835.73.4 (1.9-5.5)485162791.83.4 (2.0-5.6)Abbreviations: LRI, lower respiratory infection; MALRI, medically attended lower respiratory infection, both inpatient and outpatient cases; RSV, respiratory syncytial virus. a Full analysis set population shown. One month was defined as 30 days, 5 months were defined as 150 days, and 6 months were defined as 180 days. b Number of participants randomized and dosed with clesrovimab or palivizumab c Number of participants eligible for inclusion in the full analysis set population d Confidence intervals were estimated by exact Poisson confidence limits. RSV-Associated Disease Incidence Rates for Season 1 (Full Analysis Set Population)a Abbreviations: LRI, lower respiratory infection; MALRI, medically attended lower respiratory infection, both inpatient and outpatient cases; RSV, respiratory syncytial virus. Full analysis set population shown. One month was defined as 30 days, 5 months were defined as 150 days, and 6 months were defined as 180 days. Number of participants randomized and dosed with clesrovimab or palivizumab Number of participants eligible for inclusion in the full analysis set population Confidence intervals were estimated by exact Poisson confidence limits. Season 2 total incidence rates of RSV-associated MALRI and of RSV-associated hospitalization through day 180 after a 210-mg dose were 7.3% (95% CI, 4.4%-11.4%) and 3.0% (95% CI, 1.3%-5.9%), respectively (eTable 9 in Supplement 1), and were comparable between those who received 105 mg of clesrovimab in season 1 (MALRI: 8.6% [95% CI, 4.3%-15.4%]; hospitalization: 3.8% [95% CI, 1.2%-8.8%]) and those who received palivizumab in season 1 (MALRI: 6.0% [2.6%-11.9%]; hospitalization: 2.2% [95% CI, 0.5%-6.5%]). Incidence rates among children who participated in season 2 were comparable to their incidence rates in season 1 (eTable 10 in Supplement 1). Most children participating in season 2 had CLD or CHD, and incidence rates in season 2 were comparable to the incidence rates of CHD and CLD participants in season 1, in the clesrovimab arm (eTable 11 in Supplement 1). Amino acid substitutions at position 446 of the clesrovimab binding site in RSV F protein present at a variant allele frequency of at least 10% were detected among 3 infants who received 105 mg of clesrovimab in season 1 and 3 children who received 210 mg of clesrovimab in season 2 (eTable 12 in Supplement 1). Two participants did not meet end point criteria for RSV-associated MALRI or RSV-associated hospitalization, 1 participant met the criteria for RSV-associated MALRI, and 3 participants met the criteria for severe MALRI. PK, Pharmacodynamic, and Immunogenicity Evaluations The clesrovimab concentration-time profile in both seasons was consistent with previous results (eFigures 3 and 4 in Supplement 1).20,23,24 The peak geometric mean clesrovimab serum concentration at day 7 was 148.7 µg/mL after a 105-mg dose in season 1 and was 170.0 µg/mL after a 210-mg dose in season 2. The geometric mean clesrovimab serum concentration at day 150 was 11.8 µg/mL in season 1 and was 14.4 µg/mL in season 2. Antidrug antibodies developed in 19 of 388 infants (4.9%) at day 150 in season 1 and in 25 of 233 children (10.7%; 12 of whom received clesrovimab in season 1) at day 150 in season 2 (eTable 13 in Supplement 1). Clesrovimab PK and SNA titers were similar between ADA-positive participants and ADA-negative participants in both seasons (eFigures 5-8 in Supplement 1). There were no AESIs reported among ADA-positive participants in season 1; there was 1 ADA-positive participant with a grade 1 rash AESI in season 2. The proportions of participants with an SAE were generally comparable between ADA-negative and ADA-positive participants, suggesting that ADAs did not impact the safety profile of clesrovimab (eTables 14 and 15 in Supplement 1). Discussion In this phase 3 study, a single 105-mg dose of clesrovimab was well tolerated in infants at increased risk for severe RSV disease in their first RSV season, with a safety profile comparable to palivizumab. Furthermore, a 210-mg dose of clesrovimab given to vulnerable children requiring ongoing RSV prevention in their second RSV season was well tolerated. RSV-associated disease incidence rates were comparable after clesrovimab or palivizumab in season 1, while there was no comparator arm in season 2. Serum concentrations of clesrovimab across 2 seasons were similar to healthy infants in CLEVER, the population in which efficacy was established.20 A single-dose regimen is advantageous because it minimizes the risk of missed doses in this fragile population. The safety profile of clesrovimab reported here is consistent with findings from more than 2400 healthy, early and moderate to late preterm (≥29 to <35 weeks’ gestational age) and late preterm or full-term (≥35 weeks’ gestational age) infants who received a single 105-mg dose of clesrovimab in the phase 2b/3 trial, CLEVER.20 In CLEVER, the safety profile of clesrovimab was similar to placebo, with injection-site pain being the most common solicited injection-site AE and irritability being the most common solicited systemic AE. We previously reported prespecified interim results from SMART, at which time season 2 data were limited.23 Encouragingly, the results reported here are consistent with those interim findings. Furthermore, a 210-mg dose of clesrovimab was generally well tolerated in children who remained at increased risk for severe disease in their second year of life. The safety profile of a 210-mg second season dose of clesrovimab was comparable between children receiving clesrovimab over 2 consecutive RSV seasons and those who had received palivizumab in their first RSV season. Incidence rates across a breadth of RSV-associated disease end points were similar after a single dose of clesrovimab compared with incidence rates in participants receiving monthly palivizumab in RSV season 1. There was no comparator arm in season 2 of this study. By design, 99% of children in season 2 had CHD or CLD. Children with CHD or CLD in both infancy and in their second year of life continue to be at increased risk for RSV disease and associated complications compared with other children of the same chronological age,6,7 and this pattern was seen in this study as well. Moreover, most children (approximately 98%) who participated in season 2 were followed during post–COVID-19 pandemic seasons 2023 to 2025, which had higher rates of RSV disease compared with prepandemic seasons.27 For example, in the US, the postpandemic 2023-24 season had twice as many RSV-associated hospitalizations compared with the pre-pandemic 2018-19 season, and rates remained high for season 2024-25.28 Across both seasons, 6 participants had RSV infections with a variation in the clesrovimab binding site at position 446 of RSV F protein. RSV strains with G446E/W substitutions have reduced clesrovimab susceptibility but also reduced viral fitness, suggesting they are unlikely to increase in frequency or in the population over time.29 Characterization of G446R is ongoing. Because this study was not powered to demonstrate efficacy, efficacy of clesrovimab (105 mg) in season 1 was extrapolated to infants in this study via PK bridging from healthy infants in CLEVER.30 In CLEVER, clesrovimab reduced RSV-associated disease compared with placebo with more than 90% efficacy against RSV-associated LRI hospitalizations through 6 months.20 The serum concentration observed at day 150 after a 105-mg dose in season 1 of this trial was similar to that among healthy infants in CLEVER (10.2 µg/mL).17 Furthermore, a similar serum concentration to that in CLEVER was also observed at day 150 after a 210-mg dose of clesrovimab in season 2 of this study, further justifying that 210 mg is the appropriate dose for children who remain at risk in their second RSV season. There was no apparent impact of ADAs on clesrovimab PK, SNA, or safety, consistent with findings from CLEVER.20 Limitations This study has some limitations. First, without a comparator arm in season 2, it is challenging to interpret RSV-associated disease incidence rates after 210 mg of clesrovimab. Second, this study was not powered to assess noninferiority of clesrovimab compared with palivizumab, as that would require a prohibitively large sample size. Instead, efficacy was extrapolated to this population using PK bridging. Third, between-group comparisons for safety were not adjusted for multiplicity and should be interpreted accordingly. Finally, the potential impact of clesrovimab on long-term RSV-associated morbidity (eg, recurrent LRI, wheezing, asthma, lung function impairment) was not an objective of this study and therefore was not assessed, but it is important among these high-risk groups. Conclusions In this phase 3 randomized clinical trial, clesrovimab was generally well tolerated in infants at increased risk for severe RSV disease through 2 RSV seasons. In season 1, incidence rates of RSV-associated disease were comparable after single-dose clesrovimab or monthly palivizumab. Clesrovimab pharmacokinetics after 105 mg in season 1 and 210 mg in season 2 were comparable to those among healthy infants in CLEVER, the population for which efficacy has been demonstrated. The single-dose regimen reduces the number of injections, potentially improving adherence, an important advantage for this vulnerable population.